secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-08-17T20:15:41+00:00
Accession:  0001493152-26-038747
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma appoints Carol Brosgart, MD to board of directors
------------------------------------------------------------------

- Carol Brosgart, MD appointed to board effective August 12, 2026.
- Brings decades of antiviral therapy and epidemiology experience; contributed to FDA-approved therapies.
- Previously held roles at Gilead Sciences and Tobira; served on multiple biotech boards.
- Will guide clinical development of CDI-988 for norovirus and broader antiviral pipeline.
- Currently on boards of Galmed, Eradivir, and Merlin Biotech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226038747/0001493152-26-038747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226038747/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer